AG
CRBP icon

Aperio Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Aperio Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-513
Closed -$129K – 2383
2020
Q2 		$129K Buy
+513
New +$104K ﹤0.01% 2250
2019
Q3 		– Sell
-142
Closed -$29K – 2410
2019
Q2 		$29K Buy
+142
New +$30.4K ﹤0.01% 2628

Other funds holding CRBP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Aperio Group's CRBP Position: Q3 2020 in Review

Aperio Group sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 513 shares — an estimated $129K sold.

Aperio Group first reported a position in CRBP in Q2 2019 and held it in 2 quarters. The position peaked at $129K in Q2 2020. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

  • Aperio Group reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Aperio Group sold 513 Corbus Pharmaceuticals shares in Q3 2020, an estimated $129K.
  • Aperio Group first reported a position in Corbus Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Aperio Group's Corbus Pharmaceuticals position peaked at $129K in Q2 2020.
  • 122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Aperio Group's 13F filing for Q3 2020, filed 6 Nov 2020.